Michael S. Weiss, Chairman and CEO at KERYX BIOPHARMACEUTICALS INC (KERX), sold 84,932 shares at $14.53 ($1.2M) on 2006-12-11, disclosed to the SEC on 2006-12-11.
Scheduled sale ($1.2M) by Chairman and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.49 | 2,500 | $36K | 2.9% |
| 2 | $14.50 | 19,500 | $283K | 22.8% |
| 3 | $14.51 | 6,365 | $92K | 7.5% |
| 4 | $14.52 | 4,000 | $58K | 4.7% |
| 5 | $14.53 | 2,000 | $29K | 2.3% |
| 6 | $14.55 | 1,154 |
| $17K |
| 1.4% |
| 7 | $14.58 | 781 | $11K | 0.9% |
| 8 | $14.60 | 5,000 | $73K | 5.9% |
| 9 | $14.73 | 7,600 | $112K | 9.0% |
| 10 | $14.96 | 1,646 | $25K | 2.0% |
| 11 | $15.00 | 2,889 | $43K | 3.5% |
| 12 | $14.49 | 4,347 | $63K | 5.1% |
| 13 | $14.55 | 2,500 | $36K | 2.9% |
| 14 | $14.58 | 2,000 | $29K | 2.4% |
| 15 | $14.60 | 7,255 | $106K | 8.5% |
| 16 | $14.61 | 3,000 | $44K | 3.5% |
| 17 | $14.62 | 1,000 | $15K | 1.2% |
| 18 | $14.63 | 1,000 | $15K | 1.2% |
| 19 | $14.64 | 2,000 | $29K | 2.4% |
| 20 | $14.65 | 2,000 | $29K | 2.4% |
| 21 | $14.67 | 1,000 | $15K | 1.2% |
| 22 | $14.70 | 1,000 | $15K | 1.2% |
| 23 | $14.53 | 1,000 | $15K | 1.2% |
| 24 | $14.54 | 1,000 | $15K | 1.2% |
| 25 | $14.56 | 395 | $6K | 0.5% |
| 26 | $14.60 | 1,000 | $15K | 1.2% |
| 27 | $14.68 | 1,000 | $15K | 1.2% |
| Total | $14.59 avg | 84,932 | $1.2M | 100% |
| Filing → |
| FBIO | BUY | 2023-02-14 | $2.0M | — | Filing → |
| TGTX | SELL | 2022-01-07 | $2.6M | — | Filing → |
| TGTX | BUY | 2019-06-27 | $352K | — | Filing → |